MaxCyte Revenue Plunges 16% Amid Widening Losses, Cash Burn Accelerates

TL;DR

**MaxCyte's bleeding cash and losing revenue, making it a risky bet despite the SeQure acquisition.**

AI Summary

MaxCyte, Inc. reported a significant decline in revenue and an increased net loss for the three and nine months ended September 30, 2025. Revenue for the three months decreased to $6.829 million from $8.164 million in the prior year, a 16.4% drop. For the nine months, revenue fell to $25.726 million from $29.934 million, a 14.0% decrease. The net loss widened to $12.416 million for the three months ended September 30, 2025, compared to $11.557 million in the same period of 2024, and to $35.034 million for the nine months, up from $30.458 million. Operating expenses saw a slight decrease for the three months, from $20.289 million to $19.382 million, primarily due to reduced sales and marketing expenses (down 36.6% to $3.936 million) and general and administrative expenses (down 22.2% to $6.028 million), but were offset by a new restructuring expense of $3.058 million. The company's cash and cash equivalents significantly decreased from $27.884 million at December 31, 2024, to $12.973 million at September 30, 2025. A goodwill impairment assessment was triggered by a decline in stock price and a reduction in force, though no impairment charge was recognized. The acquisition of SeQure Dx Inc. was noted, adding goodwill of $3.554 million and intangible assets of $0.667 million to the balance sheet.

Why It Matters

MaxCyte's substantial revenue decline and increasing net losses signal significant headwinds for investors, raising concerns about the company's growth trajectory and profitability in the competitive cell therapy market. The accelerated cash burn, with cash and cash equivalents dropping from $27.884 million to $12.973 million in nine months, could impact future R&D and operational capacity. Employees might face further restructuring as evidenced by the $3.058 million expense, while customers could see potential shifts in service offerings or product development focus. The competitive landscape, where MaxCyte leverages its cell engineering platform, demands consistent innovation and market penetration, which could be challenging with these financial results.

Risk Assessment

Risk Level: high — The company reported a net loss of $35.034 million for the nine months ended September 30, 2025, an increase from $30.458 million in the prior year, indicating worsening profitability. Cash and cash equivalents plummeted from $27.884 million at December 31, 2024, to $12.973 million at September 30, 2025, representing a 53.5% decrease and a significant cash burn. Furthermore, a goodwill impairment assessment was triggered by a decline in the company's stock price and a reduction in force, highlighting underlying operational and market challenges.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to MXCT given the accelerating losses and significant cash burn. Monitor future filings closely for signs of improved revenue generation or a slowdown in cash depletion, as the current trajectory is unsustainable without further capital raises.

Financial Highlights

debt To Equity

0.18

revenue

$6.829M

operating Margin

-207.1%

total Assets

$213.476M

total Debt

$33.201M

net Income

($12.416M)

eps

($0.33)

gross Margin

76.6%

cash Position

$12.973M

revenue Growth

-16.4%

Revenue Breakdown

Key Numbers

• $6.829M — Revenue (3 months) (Decreased from $8.164M in Q3 2024, a 16.4% decline.)
• $25.726M — Revenue (9 months) (Decreased from $29.934M in the prior year, a 14.0% decline.)
• ($12.416M) — Net Loss (3 months) (Widened from ($11.557M) in Q3 2024.)
• ($35.034M) — Net Loss (9 months) (Increased from ($30.458M) in the prior year.)
• $12.973M — Cash and Cash Equivalents (Down from $27.884M at Dec 31, 2024, a 53.5% decrease.)
• $3.058M — Restructuring Expense (New expense incurred during the three and nine months ended September 30, 2025.)
• $3.554M — Goodwill (Added due to the acquisition of SeQure Dx Inc.)
• ($0.33) — Basic and Diluted Net Loss Per Share (9 months) (Increased from ($0.29) in the prior year.)
• 106,644,343 — Common Stock Shares Outstanding (As of September 30, 2025.)
• 51% — Accounts Receivable Concentration (One customer accounted for 51% of accounts receivable as of September 30, 2025.)

Key Players & Entities

• MAXCYTE, INC. (company) — registrant
• SeQure Dx Inc. (company) — acquired business
• SEC (regulator) — U.S. Securities and Exchange Commission
• Nasdaq Global Select Market (market) — stock exchange
• FASB (regulator) — Financial Accounting Standards Board
• EntreMed, Inc. (company) — former parent company
• $12,973 (dollar_amount) — cash and cash equivalents at September 30, 2025
• $35,034 (dollar_amount) — net loss for the nine months ended September 30, 2025
• $3,058 (dollar_amount) — restructuring expense for the nine months ended September 30, 2025
• $6,829 (dollar_amount) — revenue for the three months ended September 30, 2025

FAQ

Risk Factors

• Declining Revenue and Widening Net Loss [high — financial]: Revenue for the three months ended September 30, 2025, decreased by 16.4% to $6.829 million, and for the nine months, it fell 14.0% to $25.726 million. The net loss also widened to $12.416 million for the three months and $35.034 million for the nine months, indicating significant financial pressure.
• Deteriorating Cash Position [high — financial]: Cash and cash equivalents plummeted from $27.884 million at December 31, 2024, to $12.973 million at September 30, 2025, a 53.5% decrease. This rapid depletion of cash raises concerns about the company's short-term liquidity and ability to fund operations.
• Customer Concentration Risk [high — operational]: As of September 30, 2025, one customer accounted for 51% of the company's accounts receivable. This high concentration exposes MaxCyte to significant risk if this major customer experiences financial difficulties or terminates its relationship with the company.
• Goodwill Impairment Risk [medium — operational]: A decline in stock price and a reduction in force triggered an assessment for goodwill impairment. While no charge was recognized, this indicates potential overvaluation of acquired assets and a risk of future write-downs.
• Increased Operating Expenses Despite Cost Reductions [medium — financial]: Despite a reduction in sales and marketing (down 36.6%) and G&A expenses (down 22.2%), total operating expenses for the three months were only slightly down due to a new restructuring expense of $3.058 million. This highlights ongoing cost pressures and the impact of restructuring on profitability.

Industry Context

MaxCyte operates in the biotechnology tools and services sector, focusing on cell engineering technologies. The industry is characterized by rapid innovation, significant R&D investment, and a long product development cycle. Companies often rely on strategic partnerships and acquisitions to expand their platforms and market reach. Intense competition and the need for regulatory approvals are common.

Regulatory Implications

As a publicly traded company, MaxCyte is subject to SEC regulations and reporting requirements. Any misstatements or failures in financial reporting could lead to investigations and penalties. The company's operations may also be indirectly affected by regulations governing the biotechnology and pharmaceutical industries, particularly if its technologies are used in drug development or therapeutic applications.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Evaluate the sustainability of revenue decline.
3. Assess the impact of customer concentration.
4. Analyze the effectiveness of cost-saving measures.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the 10-Q, showing significant revenue decline and increased net loss.
• 2025-12-31: End of Fiscal Year 2024 — Reference point for cash and cash equivalents, which have since decreased substantially.

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair market value of its net identifiable assets. (The acquisition of SeQure Dx Inc. added $3.554 million in goodwill, which is now subject to impairment testing due to market conditions.)

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by net income. (MaxCyte's accumulated deficit increased to $251.887 million, reflecting its ongoing net losses.)

Restructuring Expense

Costs associated with significant reorganizations or shutdowns of operations, such as severance payments or facility closure costs. (A new $3.058 million restructuring expense was incurred, impacting operating expenses and net loss.)

Accounts Receivable, net

The total amount of money owed to a company by its customers for goods or services delivered, net of any allowances for doubtful accounts. (The concentration of 51% of accounts receivable with a single customer presents a significant risk.)

Year-Over-Year Comparison

Compared to the prior year, MaxCyte has experienced a notable downturn. Revenue for the three months ended September 30, 2025, declined by 16.4% to $6.829 million, and for the nine months, it decreased by 14.0% to $25.726 million. The net loss has also widened, reaching $12.416 million for the quarter and $35.034 million year-to-date. A significant concern is the drastic reduction in cash and cash equivalents, down 53.5% from $27.884 million to $12.973 million. New risks have emerged, including a potential goodwill impairment and a substantial customer concentration in accounts receivable.

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share MXCT The Nasdaq Stock Mar

Filing Documents

• mxct-20250930x10q.htm (10-Q) — 1852KB
• mxct-20250930xex31d1.htm (EX-31.1) — 15KB
• mxct-20250930xex31d2.htm (EX-31.2) — 14KB
• mxct-20250930xex32d1.htm (EX-32.1) — 7KB
• mxct-20250930xex32d2.htm (EX-32.2) — 7KB
• 0001104659-25-111396.txt ( ) — 8135KB
• mxct-20250930.xsd (EX-101.SCH) — 44KB
• mxct-20250930_cal.xml (EX-101.CAL) — 61KB
• mxct-20250930_def.xml (EX-101.DEF) — 206KB
• mxct-20250930_lab.xml (EX-101.LAB) — 442KB
• mxct-20250930_pre.xml (EX-101.PRE) — 338KB
• mxct-20250930x10q_htm.xml (XML) — 1485KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 3. Defaults Upon Senior Securities 37 Item 4. Mine Safety Disclosures 37 Item 5. Other Information 37 Item 6. Exhibits 38

Signatures

Signatures 39 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) MaxCyte, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, December 31, 2025 2024 (See Note 2) Assets Current assets: Cash and cash equivalents $ 12,973 $ 27,884 Short-term investments, at amortized cost 92,755 126,598 Accounts receivable, net 8,306 4,682 Inventory 7,611 8,914 Prepaid expenses and other current assets 3,000 3,606 Total current assets 124,645 171,684 Investments, non-current, at amortized cost 52,274 35,781 Property and equipment, net 18,620 19,707 Right-of-use asset - operating leases 11,135 10,766 Goodwill 3,554 — Intangible assets, net 667 — Other assets 2,581 1,532 Total assets $ 213,476 $ 239,470 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,286 $ 1,358 Accrued expenses and other 8,306 8,302 Operating lease liability, current 1,314 864 Deferred revenue, current portion 5,196 5,251 Total current liabilities 16,102 15,775 Operating lease liability, net of current portion 16,847 17,170 Contingent consideration 25 — Other liabilities 227 274 Total liabilities 33,201 33,219 Commitments and contingencies (Note 7) Stockholders' equity Preferred stock, $ 0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value; 400,000,000 shares authorized, 106,644,343 and 105,711,093 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1,066 1,057 Additional paid-in capital 431,096 422,047 Accumulated deficit ( 251,887 ) ( 216,853 ) Total stockholders' equity 180,275 206,251 Total liabilities and stockholders' equity $ 213,476 $ 239,470 See accompanying notes to unaudited condensed consolidated financ

View Full Filing

View this 10-Q filing on SEC EDGAR